Day: May 7, 2024

GlobalFoundries Reports First Quarter 2024 Financial Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

MALTA, N.Y., May 07, 2024 (GLOBE NEWSWIRE) — GlobalFoundries Inc. (GF) (Nasdaq: GFS) today announced preliminary financial results for the first quarter ended March 31, 2024. Key First Quarter Financial Highlights Revenue of $1.549 billion Gross margin of 25.4% and Non-IFRS gross margin(1) of 26.1% Operating margin of 9.5% and Non-IFRS operating margin(1) of 12.1% Net income of $134 million and Non-IFRS net income(1) of $174 million Non-IFRS EBITDA(1) of $577 million Cash, cash equivalents and marketable securities of $4.2 billion “In the first quarter, GF’s dedicated teams across the world delivered financial results that exceeded the high end of the guidance ranges we provided in our February earnings release,” said Dr. Thomas Caulfield, president and CEO of GF. “As pockets of the semiconductor industry...

Continue reading

Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

– Reported topline data from the investigator sponsored Phase 1 trial of intravitreal VCN-01 in pediatric patients with refractory retinoblastoma; trial results were determined to be positive by the study Monitoring Committee- -Presented preclinical data demonstrating the potential synergy between VCN-01 and liposomal irinotecan in a human pancreatic mouse xenograft at the ASGCT Annual Meeting; emphasizes VCN-01’s potential in diverse chemotherapy combinations for improved efficacy in pancreatic cancer- – VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma (PDAC), is expected to complete enrollment in the third quarter of 2024- – As of March 31, 2024, Theriva Biologics reports $18.3 million in cash, which is expected to provide runway into the...

Continue reading

Chicago Atlantic Real Estate Finance Announces First Quarter 2024 Financial Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

CHICAGO, May 07, 2024 (GLOBE NEWSWIRE) — Chicago Atlantic Real Estate Finance, Inc. (NASDAQ: REFI) (“Chicago Atlantic” or the “Company”), a commercial mortgage real estate investment trust, today announced its results for the first quarter ended March 31, 2024. John Mazarakis, Executive Chairman of Chicago Atlantic, noted, “We are thrilled with progress toward regulatory reform resulting from the recent news of the DEA’s commitment to the rescheduling of cannabis. Once enacted, the policy change is likely to bring significant benefits to the U.S. cannabis industry, including the elimination of punitive federal tax burdens, increased access to capital, and increased employment and investment opportunity to the expected benefit of our shareholders. While there is still uncertainty as to exactly how and when the rescheduling will...

Continue reading

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

Written by Customer Service on . Posted in Public Companies.

NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) — Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease, today announced that company management will participate in fireside chats at the following investor conferences: The Citizens JMP Life Sciences Conference on Monday, May 13, 2024 at 9:00 AM ETRBC Capital Markets 2024 Global Healthcare Conference on Tuesday, May 14, 2024 at 11:00 AM ETBank of America Securities 2024 Health Care Conference on Wednesday, May 15, 2024 at 8:40 AM PT The events will be webcast live under the News & Events tab in the Investors section of our website. Replays of the webcasts will be available on the website following the presentations. About Lexeo TherapeuticsLexeo...

Continue reading

Amesite Announces Strategic Five-Year Partnership with Franciscan Missionaries of Our Lady University to Deliver Healthcare Training for Healthcare Professionals

Written by Customer Service on . Posted in Public Companies.

Franciscan Missionaries of Our Lady University is Sixth Contract Win Since Introducing No Setup-fee Plan DETROIT, May 07, 2024 (GLOBE NEWSWIRE) — Amesite Inc. (NASDAQ: AMST), a leading artificial intelligence software company offering a cloud-based learning platform for business and education markets, announces a five-year (5) partnership with Franciscan Missionaries of Our Lady University to deliver healthcare training programs for working healthcare professionals in subjects ranging from leadership and management, quality improvement, healthcare finance, nursing continuing education (CNE), physical therapy continuing education, ethics in medicine and continuing medical education (CME). “As we seek to expand our mission to educate healthcare professionals and form Franciscan servant leaders of all faiths we are honored to partner...

Continue reading

Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Generated $172.3 million in 1Q 2024 revenues, including $163.1 million in U.S. net product sales $137.5 million for SYFOVRE® (pegcetacoplan injection) $25.6 million for EMPAVELI® (pegcetacoplan) Anticipates CHMP opinion for pegcetacoplan in GA no later than July 2024 On track to report topline Phase 3 data with systemic pegcetacoplan in C3G / IC-MPGN in mid-2024 Cash and cash equivalents of $325.9 million as of March 31, 2024; projected revenues and cash expected to be sufficient to fund operations for foreseeable future Management to host conference call today at 8:30 a.m. ET WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its first quarter 2024 financial results and business highlights. “We made excellent progress against our strategic priorities during the...

Continue reading

uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

~ On track to initiate FDA interaction regarding AMT-130 in second quarter of 2024 and provide a clinical update from the Phase I/II trials in mid-2024 ~ ~ Clinical trial initiation for Fabry disease on track to begin in second quarter of 2024, followed by refractory mesial temporal lobe epilepsy and SOD1-ALS in third quarter of 2024 ~ ~ Comprehensive review of operations and options to reduce expenses underway and expected to be completed in mid-2024 ~ LEXINGTON, Mass. and AMSTERDAM, May 07, 2024 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the first quarter of 2024 and highlighted recent progress across its business. “In the first quarter, we made solid progress across three key...

Continue reading

Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

First-in-class IV SMARCA2 degrader, PRT3789 and potentially best-in-class CDK9 inhibitor, PRT2527 remain on track to generate initial proof-of-concept data in 2024  New preclinical data presented at AACR 2024 included first characterization of PRT7732, a highly-selective, orally bioavailable SMARCA2 degrader Operational leadership capabilities further strengthened by recent hires Chief Business Officer Sean Brusky and Senior Vice President, Investor Relations Robert Doody Current cash runway into 2026 with $201.9 million in cash, cash equivalents and marketable securities as of March 31, 2024  WILMINGTON, Del., May 07, 2024 (GLOBE NEWSWIRE) — Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for the first quarter ended March 31, 2024 and provided...

Continue reading

Ashland signs definitive agreement to sell nutraceuticals business to Turnspire Capital Partners

Written by Customer Service on . Posted in Public Companies.

WILMINGTON, Del., May 07, 2024 (GLOBE NEWSWIRE) — Ashland Inc. (NYSE: ASH) announced today that it has signed a definitive agreement to sell its nutraceuticals business to Turnspire Capital Partners LLC (“Turnspire”). The transaction is expected to close in the calendar third quarter 2024, subject to the satisfaction of customary closing conditions. Ashland’s nutraceuticals business supplies a broad portfolio of active ingredients and formulation aids to nutritional product companies, as well as custom formulation and contract manufacturing capabilities for the nutrition market, from four production facilities in New Jersey and Utah in the United States, and Tamaulipas, Mexico. “The nutraceuticals business has a strong portfolio of proprietary ingredients, formulation and manufacturing capabilities, and a dedicated team that...

Continue reading

Asensus Surgical, Inc. Schedules First Quarter Financial and Operating Results Conference Call for May 14, 2024

Written by Customer Service on . Posted in Public Companies.

RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) — Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced today that it plans to release 2024 first quarter financial and operating results after the market closes on Tuesday, May 14, 2024. The Company will host a conference call to discuss these results starting at 4:30 p.m. ET the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial 1-888-886-7786 for domestic callers and 416-764-8658 for international callers, approximately ten minutes prior to the start time. To access the live audio webcast or archived recording, use the following link https://ir.asensus.com/events-and-presentations. The replay will be available...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.